Form 483

Vivex Biologics, Inc. Form 483, 2022-08-04

FDA issued a Form 483 to Vivex Biologics, Inc. on 2022-08-04 with 4 public-safe observations.

483· Form 483 issuedBiologics4 observations

Vivex Biologics, Inc. · Miami, United States · Issued August 4, 2022

Overview

  • 4 public-safe observations are available for this inspection.
  • 1 structured CFR citation is represented.
  • 4 investigators are tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

4 Aug 2022
21 CFR 1271.190(a)

State of repair

Cited by Christopher J Adams, Lura D Baquero, Lura D Kelly, Sergio E Delgado

4 Aug 2022
21 CFR 1271.190(a)

State of repair

Cited by Christopher J Adams, Lura D Baquero, Lura D Kelly, Sergio E Delgado

4 Aug 2022
21 CFR 1271.190(a)

State of repair

Cited by Christopher J Adams, Lura D Baquero, Lura D Kelly, Sergio E Delgado

4 Aug 2022
21 CFR 1271.190(a)

State of repair

Cited by Christopher J Adams, Lura D Baquero, Lura D Kelly, Sergio E Delgado

Inspected site

VBVivex Biologics, Inc.Miami, United States

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 1271.190(a)Cited across public-safe Form 483 observations4x

Source document

PDF
PDF available

Form 483 source document

The source document is available to authorized Atlas users.

Full 483 report

Get the verbatim text of all 4 observations

The source PDF, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere